SGMT
Sagimet Biosciences Inc. Series A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$182.15M
P/E Ratio
—
EPS
$-1.58
Beta
3.21
52W High
$11.41
52W Low
$2.02
50-Day MA
$5.42
200-Day MA
$7.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc. (SGMT) is a cutting-edge biotechnology firm specializing in the development of innovative therapies for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through clinical trials, leveraging novel mechanisms aimed at significantly improving patient outcomes. With a seasoned leadership team and a comprehensive intellectual property portfolio, Sagimet is well-positioned to take advantage of the growing demand for effective treatments in the metabolic disease arena, presenting a promising opportunity for institutional investors looking to engage with the evolving biotech market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -38.20% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.42 |
| Price-to-Book | 1.55 |
| Price-to-Sales (TTM) | 52.50 |
| EV/Revenue | 0.276 |
| EV/EBITDA | -1.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $32.02M |
| Float | $29.98M |
| % Insiders | 6.37% |
| % Institutions | 45.03% |
Analyst Ratings
Consensus ($25.78 target)
1
Strong Buy8
Buy1
HoldData last updated: 4/9/2026